Kexing Biopharm Showcases Innovation at CPHI Milan 2024
Kexing Biopharm, a prominent Chinese biopharmaceutical company, made a significant impact at the International Convention on Pharmaceutical Ingredients and Intermediates Europe Exhibition, held in Milan. This event, known as CPHI Milan 2024, is recognized as one of the premier pharmaceutical industry gatherings worldwide. Kexing's participation underscored its commitment to advancing healthcare solutions through innovation.
Diverse Product Line Highlighted at the Event
Under the leadership of General Manager Mr. Zhao Yanqing, Kexing Biopharm displayed a comprehensive portfolio of products that span various therapeutic areas including oncology, autoimmunity, and metabolism. The event featured critical advancements from Kexing, showcasing essential products like human erythropoietin (EPO), human granulocyte colony-stimulating factor (GC), and albumin-bound paclitaxel, branded as Apexelsin®. Each product reflects Kexing's dedication to quality and therapeutic efficacy.
Launch of Apexelsin® in the European Market
The highlight of Kexing's appearance was the formal launch ceremony for Apexelsin®, a groundbreaking product designed for cancer treatment. Following rigorous compliance with EU pharmaceutical GMP standards, Kexing Biopharm has successfully established a new production line for Apexelsin®. By securing the EU pharmaceutical GMP certificate earlier this year and achieving marketing approval in July, Kexing has positioned itself on a promising path for growth and accessibility in the European market.
Apexelsin®: A Milestone in Cancer Treatment
With the shipment of Apexelsin® having commenced in August, Kexing Biopharm has officially penetrated the European pharmaceutical market. This advancement not only highlights Kexing's capabilities in the realm of international expansions but also reflects its continuous efforts to enhance global healthcare, particularly in oncology. The successful launch signifies an important stride in Kexing's strategic vision of globalization within the pharmaceutical industry.
Strengthening International Partnerships
During the exhibition, Kexing Biopharm also marked a significant partnership with representatives from Saudi Arabia, further solidifying its presence in the Middle East. This collaboration aims to expand the scope of pharmaceutical offerings and innovative solutions in the region. Kexing Biopharm's representative expressed optimism about the future of this partnership, indicating a mutual commitment to progressing in pharmaceutical advancements.
Kexing Biopharm's Commitment to Global Innovation
Kexing Biopharm stands firm on its commitment to innovation and internationalization as core principles of development. The company actively seeks opportunities to collaborate with global stakeholders, enabling the licensing of high-quality blockbuster drugs and fostering innovative advancements. Kexing's vision of global growth is evident in its initiatives to enhance communication and cooperation across the pharmaceutical landscape.
Frequently Asked Questions
1. What products did Kexing Biopharm showcase at CPHI Milan 2024?
Kexing Biopharm showcased a variety of products, including human erythropoietin, granulocyte colony-stimulating factor, and albumin-bound paclitaxel (Apexelsin®).
2. What is Apexelsin®?
Apexelsin® is an albumin-bound paclitaxel product launched by Kexing Biopharm for cancer treatment, compliant with EU pharmaceutical GMP standards.
3. How has Kexing Biopharm expanded its product reach in Europe?
Kexing has established a new production line for Apexelsin® based on EU standards and has begun shipping the product, marking its entry into the European market.
4. What strategic partnerships has Kexing Biopharm formed recently?
Kexing Biopharm has formed a partnership with representatives from Saudi Arabia to enhance collaboration on pharmaceutical developments in the Middle East.
5. What is Kexing Biopharm's vision for the future?
Kexing Biopharm aims to innovate and internationalize, focusing on collaboration with global partners to promote advancements in the pharmaceutical industry.